<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37216202</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1523-2859</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>1677</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>29</Day></PubDate></JournalIssue><Title>The Medical letter on drugs and therapeutics</Title><ISOAbbreviation>Med Lett Drugs Ther</ISOAbbreviation></Journal><ArticleTitle>COVID-19 update: Metformin to prevent long COVID?</ArticleTitle><Pagination><StartPage>87</StartPage><EndPage>88</EndPage><MedlinePgn>87-88</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.58347/tml.2023.1677e</ELocationID><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Lett Drugs Ther</MedlineTA><NlmUniqueID>2985240R</NlmUniqueID><ISSNLinking>0025-732X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9100L32L2N</RegistryNumber><NameOfSubstance UI="D008687">Metformin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>70288-86-7</RegistryNumber><NameOfSubstance UI="D007559">Ivermectin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008687" MajorTopicYN="Y">Metformin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007559" MajorTopicYN="N">Ivermectin</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">adverse effects</Keyword><Keyword MajorTopicYN="N">dosage</Keyword><Keyword MajorTopicYN="N">drug interactions</Keyword><Keyword MajorTopicYN="N">efficacy</Keyword><Keyword MajorTopicYN="N">fluvoxamine</Keyword><Keyword MajorTopicYN="N">ivermectin</Keyword><Keyword MajorTopicYN="N">metformin</Keyword><Keyword MajorTopicYN="N">safety</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>22</Day><Hour>19</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>22</Day><Hour>12</Hour><Minute>37</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37216202</ArticleId><ArticleId IdType="doi">10.58347/tml.2023.1677e</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>